The TOAD trial: follow-up data on quality of life

Some 15 months ago, we reported the initial, primary results of the TOAD trial, which showed an overall survival benefit for immediate as opposed to delayed initiation of androgen deprivation therapy (ADT) in non-metastatic patients considered to be inappropriate for curative therapy. … READ MORE …

Primary ADT in treatment of elderly men with organ-confined prostate cancer

One really has to wonder whether we are still treating elderly men, initially diagnosed with organ-confined prostate cancer, with first-line or “primary” androgen deprivation therapy ADT)! And if we are, why on Earth is that? … READ MORE …

“How are you feeling?” can be an important question for men on ADT

At the upcoming meeting of the American Society for Clincial Oncology (ASCO) meeting in Chicago, Dr. Alicia Morgans of Vanderbilt University will be speaking about the physical and cognitive effects of systemic therapy in older men with prostate cancer. … READ MORE …

New test for abiraterone- and enzalutamide-resistant forms of prostate cancer

A group at The Institute for Cancer Research and The Royal Marsden Hospital in the UK — along with other European colleagues — has come up with a new, relatively low-cost test that seems to be able to identify men with advanced forms of prostate cancer who are more or less likely to respond well to treatment with drugs like abirateone acetate and enzalutamide. … READ MORE …

Yes guys … exercise is good for men on ADT!

It has long been understood that taking regular exercise can be helpful in management of risk for fatigue among men being treated with androgen deprivation therapy (ADT) for prostate cancer — whatever the stage of prostate cancer that the patient is being treated for. … READ MORE …

Conference call/webinar on bipolar androgen therapy (BAT)

For those who are interested, the Answer Cancer Foundation has let us know that they will be holding an educational conference call/webinar at 8:00 pm Eastern (5:00 pm Pacific) today on the subject of bipolar androgen therapy in the treatment of advanced prostate cancer. … READ MORE …

Aggressive, neoadjuvant androgen ablation prior to surgery in higher risk prostate cancer patients

The development of drugs like abiraterone acetate and enzalutamide has stimulated new research into the use of such agents early on, in combination with first-line therapy, to see if it can affect the outcomes for men with high-risk and unfavorable intermediate-risk prostate cancer. … READ MORE …